Cidara Therapeutics Stock Today
| CDTX Stock | USD 20.20 0.61 3.11% |
Performance17 of 100
| Odds Of DistressLess than 6
|
Cidara Therapeutics is trading at 20.20 as of the 28th of November 2024; that is 3.11 percent increase since the beginning of the trading day. The stock's open price was 19.59. Cidara Therapeutics has only a 6 % chance of going through financial distress over the next few years and had a solid performance during the last 90 days. Equity ratings for Cidara Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of September 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of April 2015 | Category Healthcare | Classification Health Care |
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. Cidara Therapeutics, Inc. The company has 10.94 M outstanding shares of which 49.83 K shares are currently shorted by private and institutional investors with about 3.88 trading days to cover. More on Cidara Therapeutics
Moving together with Cidara Stock
| 0.68 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Cidara Stock
Cidara Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Jeffrey Stein | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCidara Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cidara Therapeutics' financial leverage. It provides some insight into what part of Cidara Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cidara Therapeutics (CDTX) is traded on NASDAQ Exchange in USA. It is located in 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121 and employs 69 people. Cidara Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 220.97 M. Cidara Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.94 M outstanding shares of which 49.83 K shares are currently shorted by private and institutional investors with about 3.88 trading days to cover.
Cidara Therapeutics currently holds about 53.08 M in cash with (22.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74.
Check Cidara Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Cidara Therapeutics is $220.97 Million. Over half of Cidara Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Cidara Ownership Details
Cidara Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-09-30 | 31.8 K | |
| Schonfeld Strategic Advisors Llc | 2024-09-30 | 19.5 K | |
| State Street Corp | 2024-06-30 | 13.6 K | |
| U.s. Bancorp | 2024-06-30 | 13.1 K | |
| Ubs Group Ag | 2024-06-30 | 1.5 K | |
| Acadian Asset Management Llc | 2024-06-30 | 855 | |
| Tower Research Capital Llc | 2024-06-30 | 746 | |
| Manchester Capital Management Llc | 2024-09-30 | 470 | |
| Pacifica Partners Inc | 2024-09-30 | 400 | |
| Ra Capital Management, Llc | 2024-09-30 | 703.1 K | |
| Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 703.1 K |
Cidara Therapeutics Historical Income Statement
Cidara Stock Against Markets
Cidara Therapeutics Corporate Management
| Carol Waldo | VP Assurance | Profile | |
| James Balkovec | VP Research | Profile | |
| Taylor Sandison | Acting Chief Medical Officer | Profile | |
| SPHR CCP | Senior Culture | Profile | |
| Jim MBA | Chief Officer | Profile |
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.